{
    "clinical_study": {
        "@rank": "43369", 
        "arm_group": [
            {
                "arm_group_label": "NNC0114-0006", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "This trial is conducted in Europe and the United States of America (USA). The aim of the\n      trial is to investigate the safety and tolerability of NNC0114-0006 in subjects with\n      systemic lupus erythematosus (SLE) concomitantly treated with stable background therapies."
        }, 
        "brief_title": "An Investigation of Safety and Tolerability of NNC0114-0006 in Subjects With Systemic Lupus Erythematosus (SLE)", 
        "completion_date": {
            "#text": "February 2014", 
            "@type": "Actual"
        }, 
        "condition": [
            "Inflammation", 
            "Systemic Lupus Erythematosus"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Inflammation", 
                "Lupus Erythematosus, Systemic"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Men and women (not pregnant and not nursing)\n\n          -  Subjects with SLE meeting the American College of Rheumatology (ACR) criteria, with a\n             disease duration of at least 6 months\n\n          -  Subjects with clinically active SLE defined as a Safety of Estrogens in Lupus\n             Erythematosus National Assessment (SELENA)-Systemic Lupus Erythematosus Disease\n             Activity Index (SLEDAI) score of at least 6 and positive for antinuclear antibody\n             (ANA) and/or Anti-double-stranded DNA antibody (anti-dsDNA)\n\n          -  If taken, background medication must be stable\n\n        Exclusion Criteria:\n\n          -  Presence or history of active lupus nephritis (LN) within the last 4 months or active\n             central nervous system (CNS) disease within the last 12 months\n\n          -  Body mass index (BMI) below 18 kg/m^2 or above 38 kg/m^2"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "64 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "10", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "September 14, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01689025", 
            "org_study_id": "NN8828-4002", 
            "secondary_id": [
                "2011-005699-41", 
                "U1111-1125-9646"
            ]
        }, 
        "intervention": [
            {
                "arm_group_label": "NNC0114-0006", 
                "description": "Administered subcutaneously (s.c., under the skin) every second week to a total of four doses.", 
                "intervention_name": "NNC0114-0006", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Administered subcutaneously (s.c., under the skin) every second week to a total of four doses.", 
                "intervention_name": "placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "April 7, 2014", 
        "link": {
            "description": "Clinical Trials at Novo Nordisk", 
            "url": "http://novonordisk-trials.com"
        }, 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "La Jolla", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "92093"
                    }, 
                    "name": "Novo Nordisk Clinical Trial Call Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Houston", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "77034"
                    }, 
                    "name": "Novo Nordisk Clinical Trial Call Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Szeged", 
                        "country": "Hungary", 
                        "zip": "6720"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Poznan", 
                        "country": "Poland", 
                        "zip": "60-218"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Belgrade", 
                        "country": "Serbia", 
                        "zip": "11000"
                    }
                }
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Hungary", 
                "Poland", 
                "Serbia"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomised, Placebo-controlled, Double-blind, Multiple-dose, Dose-escalation Trial Investigating the Safety and Tolerability of NNC0114-0006 in Subjects With Systemic Lupus Erythematosus", 
        "overall_official": {
            "affiliation": "Novo Nordisk A/S", 
            "last_name": "Global Clinical Registry (GCR, 1452)", 
            "role": "Study Director"
        }, 
        "overall_status": "Terminated", 
        "oversight_info": {
            "authority": [
                "Hungary: Ministry of Health, Social and Family Affairs", 
                "Poland: Ministry of Health and Social Security", 
                "Serbia: Medicines and Medical Devices Agency of Serbia", 
                "United States: Food and Drug Administration"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "February 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Incidence of Adverse Events (AEs)", 
            "safety_issue": "No", 
            "time_frame": "From first administration of the trial product and up to week 26"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01689025"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "PK endpoint from serum NNC0114-0006: Terminal elimination half-life (t\u00bd)", 
                "safety_issue": "No", 
                "time_frame": "After the last dosing (Week 6)"
            }, 
            {
                "measure": "PK endpoint from serum NNC0114-0006: Accumulation based on the concentration", 
                "safety_issue": "No", 
                "time_frame": "2 weeks after the first (week 2) and the last dose (week 8)"
            }, 
            {
                "measure": "Change in serum levels of total IL-21 (Interleukin-21)", 
                "safety_issue": "No", 
                "time_frame": "Week 0, week 26"
            }, 
            {
                "measure": "Change in disease activity (SELENA-SLEDAI)", 
                "safety_issue": "No", 
                "time_frame": "Week 0, week 12"
            }, 
            {
                "measure": "Change in corticosteroid usage", 
                "safety_issue": "No", 
                "time_frame": "Week 0, week 12"
            }
        ], 
        "source": "Novo Nordisk A/S", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Novo Nordisk A/S", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "September 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}